Today is World Thrombosis Day! It’s time to take control of your health and raise awareness about blood clots. Remember, "From Head to Toe, Take Control: Prevent Thrombosis, Protect Your Health." Our countdown is over, but our mission is just beginning. Share how you’re joining

🚨Tomorrow is #WorldThrombosisDay🚨 🎧to the latest @isth Pulse Podcast w/Lai Heng Lee 🇸🇬 & @bhwords 🇬🇧 as they share global insights on hospital-associated #VTE prevention, highlight gaps in care, & explore opport. for improvement #WTDay25 @thrombosisday https://t.co/amzwNC4teG

Last call! 🚨Tomorrow is the final day to apply for the ISTH @INVENT_VTE Training Fellowship Program. 👉 Apply before the deadline: https://t.co/1znLSttbKd

🚀 This is your friendly reminder that applications are open for the ISTH Training Fellowship Program, including a joint fellowship with @INVENT_VTE! 👉 Learn more: https://t.co/1znLSttbKd

Radiotherapy is essential in cancer care, but evidence shows it may independently raise the risk of VTE. 🩸⚡ This review in @RPTHjournal highlights mechanisms, diagnostic challenges, and why tailored thromboprophylaxis, not blanket use, is needed. 👉 https://t.co/JI8fmmvevl

🫁 Derivation and Validation of a COPD-specific Pulmonary Embolism Diagnostic Strategy ⬇️ 📌 Mai et al. derived a #COPD-specific algorithm 📌 Diagnostic failure rate: 0.9%; 53.4% patients would need imaging to rule out #PE 👉 https://t.co/4D3MJ9fx0c #VTE #Thrombosis

Be part of a research planning meeting focusing on reducing the risk of #thrombosis https://t.co/u29elJxKYU

🚨 SPECTACULAR RCT at #ISTH2025! Although non-inferiority to CTPA wasn’t shown, a negative SPECT V/Q scan led to low 3-month VTE risk ✅ Supporting the safety of ruling out PE with a SPECT-based algorithm SPECTacular findings indeed! 🫁💥

🩸 New insights from the RENOVE trial (extended duration anticoagulation) at #ISTH2025: 📉 Reduced-dose DOAC is non-inferior in patients with BMI <30, with less bleeding risk. ⚠️ But in patients with BMI ≥30, reduced-dose may be inferior for bleeding and recurrent VTE. ➡️

📢 Practice-changing data from the Adjust-DVT study! ✅ Age-adjusted D-dimer safely rules out DVT in low/non-high pretest probability patients 📉 Reduces unnecessary ultrasounds 🔍 +17% yield in patients ≥75 years #ISTH2025 #DVT #Thrombosis #LessIsMore

🩸 Clots tend to come back at the same site as the index VTE! Among 708 patients with prior VTE, recurrences often occurred at the same site as the original event, especially ipsilateral DVTs. Familiar symptoms? Trust your clinical instincts. #ISTH2025 #VTE #DVT

At #ISTH2025 ? Don’t miss Prof. Le Gal present on the network endorsed Adjust-#DVT study at 10:30 am ET in room 146 A-C. An incredible multi-national research achievement! #thrombosis #research

🫁 A COPD-specific diagnostic strategy for PE was retrospectively validated and found to be safe using a 3-item score + D-dimer with 2 cut-offs, 50% of patients avoided imaging. 🔍 Signs of DVT, non-purulent AECOPD, and PE as most likely dx #ISTH2025 #VTE #COPD

🩸 Meta-analysis presented at #ISTH2025 and simultaneously published in @ehj_ed found that several risk factors (e.g., previous history of VTE or bleeding, advanced cancer, and specific cancer sites) are associated with recurrent VTE and bleeding in patients with CAT.

Starting soon ! Join us in room 203 A&B or via the live stream below https://t.co/WyqzZegrr6

Hot off the press! COBBRA trial showed that apixaban is associated with >50% reduced risk of clinically-relevant bleeding symptoms for acute VTE treatment. This can be practice changing! @LanaCastellucci @RodgerMarc @canvector

Is this the end of rivaroxaban for acute VTE? @LanaCastellucci presenting the COBBRA trial - 1st RCT comparing apixaban to riva over 3 months. 56% reduction in bleeding risk with apixaban. A safer Rx with the same efficacy. #ISTH2025

Amazing achievement 😱 Congratulations @LanaCastellucci and Al the @canvector network 👏

@THANZBlood Congratulations @LanaCastellucci and the entire study team ! Incredible work on this pivotal trial !

Late breaking abstract session at #ISTH2025. COBRRA results are in! 50% reduction in bleeding with Apixaban use for acute VTE compared to Rivaroxaban. @THANZBlood members were co-investigators on this study, an enormous effort.